Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

BACKGROUND: It is widely recognised that sorafenib inhibits a range of molecular targets in renal cell carcinoma (RCC). In this study, we aim to use patient-derived RCC xenografts to delineate the angiogenic and non-angiogenic molecular targets of sorafenib therapy for advanced RCC (aRCC). METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yuen, J S P, Sim, M Y, Siml, H G, Chong, T W, Lau, W K O, Cheng, C W S, Huynh, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3065286/
https://ncbi.nlm.nih.gov/pubmed/21407223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.55
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados